Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1995 1
1996 2
2012 1
2013 1
2015 1
2017 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
3-Year Clinical Outcomes of the PRISON-IV Trial: Ultrathin Struts Versus Conventional Drug-Eluting Stents in Total Coronary Occlusions.
Zivelonghi C, Agostoni P, Teeuwen K, van der Schaaf RJ, Henriques JPS, Vermeersch PHMJ, Bosschaert MAR, Kelder JC, Tijssen JGP, Suttorp MJ. Zivelonghi C, et al. Among authors: vermeersch phmj. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1747-1749. doi: 10.1016/j.jcin.2019.05.044. JACC Cardiovasc Interv. 2019. PMID: 31488307 Free article. Clinical Trial. No abstract available.
Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K, van der Schaaf RJ, Adriaenssens T, Koolen JJ, Smits PC, Henriques JP, Vermeersch PH, Tjon Joe Gin RM, Schölzel BE, Kelder JC, Tijssen JG, Agostoni P, Suttorp MJ. Teeuwen K, et al. Among authors: vermeersch ph. JACC Cardiovasc Interv. 2017 Jan 23;10(2):133-143. doi: 10.1016/j.jcin.2016.10.017. JACC Cardiovasc Interv. 2017. PMID: 28104206 Free article. Clinical Trial.
Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
Van den Branden BJ, Teeuwen K, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ. Van den Branden BJ, et al. Among authors: vermeersch ph. EuroIntervention. 2013 Nov;9(7):841-53. doi: 10.4244/EIJV9I7A138. EuroIntervention. 2013. PMID: 23628457 Free article.
Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
Teeuwen K, Van den Branden BJ, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ. Teeuwen K, et al. Among authors: vermeersch ph. EuroIntervention. 2015 Mar;10(11):1272-5. doi: 10.4244/EIJY14M08_07. EuroIntervention. 2015. PMID: 25136884 Free article. Clinical Trial.
A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
Teeuwen K, Adriaenssens T, Van den Branden BJ, Henriques JP, Van der Schaaf RJ, Koolen JJ, Vermeersch PH, Bosschaert MA, Tijssen JG, Suttorp MJ. Teeuwen K, et al. Among authors: vermeersch ph. Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240. Trials. 2012. PMID: 23241457 Free PMC article. Clinical Trial.
[Cardiac myxoma in 13 patients].
Paelinck BP, Vermeersch PH, Convens CG, Van Cauwelaert PA, Van Den Branden FL. Paelinck BP, et al. Among authors: vermeersch ph. Ned Tijdschr Geneeskd. 1995 Sep 23;139(38):1931-5. Ned Tijdschr Geneeskd. 1995. PMID: 7477533 Dutch.
12 results